CDSCO Panel Recommends Protocol Amendment for Novartis' Ianalumab Trial Farhat Nasim21 May 2025 8:03 PM ISTNew Delhi: The Subject Expert Committee (SEC) on Haematology, functional under the Central Drugs Standard Control Organisation (CDSCO) has recommended...
CDSCO Panel Approves Novartis Protocol Amendment Proposal fo Ianalumab study Dr. Divya Colin2 April 2025 5:30 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the protocol...
CDSCO Panel Approves Novartis Protocol Amendment Proposal for Ianalumab Study Dr. Divya Colin23 Dec 2024 6:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has approved the drug major...
CDSCO Panel Approves Novartis's Protocol Amendment Proposal to Study Ianalumab Dr. Divya Colin1 Nov 2024 5:45 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major...
CDSCO Panel Approves Novartis Protocol Amendment Proposal To Study Ianalumab Dr. Divya Colin28 Jun 2024 5:30 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major...
CDSCO Panel Grants Novartis Protocol Amendment Proposal For Ianalumab Dr. Divya Colin27 April 2024 6:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major...
Novartis Gets CDSCO panel okay To Study Monoclonal Antibody Ianalumab Dr. Divya Colin17 Jun 2023 6:00 PM ISTNew Delhi: The drug major Novartis has got the green signal from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
Novartis gets CDSCO panel nod for Phase III CT of anticancer drug Ianalumab Dr. Divya Colin23 March 2023 6:00 PM ISTNew Delhi: In a significant development, pharmaceutical major Novartis has got the go-ahead from the Subject Expert Committee (SEC) functional under...
Novartis Gets CDSCO Panel Nod To Study Ianalumab Dr. Divya Colin4 Sept 2022 11:17 AM ISTNew Delhi: In a significant development, drug major Novartis has got a green signal from the Subject Expert Committee (SEC) functional under the...
SC Ianalumab considered safe, effective in Sjögren's syndrome Dr. Nandita Mohan11 Dec 2021 7:55 AM ISTFindings from a recent trial showed ianalumab to be safe and well-tolerated in patients with moderate to severe primary Sjogren's syndrome. The study...
Medical Bulletin 9/December/2021 Dr. Nandita Mohan10 Dec 2021 12:48 PM ISTHere are Top Medical stories of the dayPatients with high cholesterol and triglycerides more prone to perioperative retinal vein occlusionPatients...
Subcutaneous ianalumab safe and effective for Sjogren's syndrome: Lancet Medha Baranwal6 Dec 2021 9:00 AM ISTUSA: Findings from a recent trial showed ianalumab to be safe and well-tolerated in patients with moderate to severe primary Sjogren's syndrome. The...
